PedAM
Pediatric Disease Annotations & Medicines
| myofascial pain syndrome | ||||
| Disease ID | 492 |
|---|---|
| Disease | myofascial pain syndrome |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:6) HP:0003418 | Back pain | 3 HP:0003419 | Low back pain | 2 HP:0012531 | Pain | 2 HP:0012721 | Venous malformations | 1 HP:0010628 | Facial palsy, unilateral or bilateral | 1 HP:0012329 | Angioblastoma | 1 |
| Disease ID | 492 |
|---|---|
| Disease | myofascial pain syndrome |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:22) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1799971 | 24671502 | 4988 | OPRM1 | umls:C0016053 | BeFree | Assessment of opioid receptor μ1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia. | 0.005634266 | 2014 | OPRM1 | 6 | 154039662 | A | G |
| rs1799983 | 16951945 | 4846 | NOS3 | umls:C0016053 | BeFree | No evidence for an association between the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and fibromyalgia syndrome. | 0.002995792 | 2007 | NOS3 | 7 | 150999023 | T | G |
| rs3771863 | 25786041 | 6869 | TACR1 | umls:C0016053 | BeFree | The rs3771863 single nucleotide polymorphism of the TACR1 gene is associated to a lower risk of sicca syndrome in fibromyalgia patients. | 0.002638474 | 2014 | TACR1;LOC105374811 | 2 | 75192588 | C | T |
| rs386602118 | 21773883 | 627 | BDNF | umls:C0016053 | BeFree | A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein. | 0.002995792 | 2012 | NA | NA | NA | NA | NA |
| rs386602276 | 21120487 | 3356 | HTR2A | umls:C0016053 | BeFree | This meta-analysis demonstrates that the 5-HT2A receptor 102T/C polymorphism confers susceptibility to fibromyalgia. | 0.003995683 | 2012 | NA | NA | NA | NA | NA |
| rs386602276 | 11732859 | 3356 | HTR2A | umls:C0016053 | BeFree | Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. | 0.003995683 | 2001 | NA | NA | NA | NA | NA |
| rs386602276 | 22124593 | 3356 | HTR2A | umls:C0016053 | BeFree | Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility. | 0.003995683 | 2011 | NA | NA | NA | NA | NA |
| rs386602276 | 10527809 | 3356 | HTR2A | umls:C0016053 | BeFree | The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. | 0.003995683 | 1999 | NA | NA | NA | NA | NA |
| rs4680 | 23025981 | 1312 | COMT | umls:C0016053 | BeFree | Catechol-O-methyltransferase Val158Met polymorphism influences anxiety, depression, and disability, but not pressure pain sensitivity, in women with fibromyalgia syndrome. | 0.023451079 | 2012 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 24762091 | 1312 | COMT | umls:C0016053 | BeFree | Clinical symptoms in fibromyalgia are associated to catechol-O-methyltransferase (COMT) gene Val158Met polymorphism. | 0.023451079 | 2015 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 21120493 | 1312 | COMT | umls:C0016053 | BeFree | These results suggest that SNPs rs4680 and rs4818 of the COMT gene may be associated with fibromyalgia and pain sensitivity in FS Brazilian patients. | 0.023451079 | 2012 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 20074440 | 1312 | COMT | umls:C0016053 | BeFree | The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. | 0.023451079 | 2009 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 24503977 | 1312 | COMT | umls:C0016053 | BeFree | Has catechol-O-methyltransferase genotype (Val158Met) an influence on endocrine, sympathetic nervous and humoral immune systems in women with fibromyalgia syndrome? | 0.023451079 | 2014 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 18196244 | 3356 | HTR2A | umls:C0016053 | BeFree | The objective of this study was to determine the potential effects of single nucleotide polymorphisms (SNPs) in catechol-O-methyltransferase (COMT) (rs4680) and 5-hydroxytryptamine (serotonin) 2A (5-HT2A) receptor (rs6313 and rs6311) genes on susceptibility to FMS. | 0.003995683 | 2008 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4680 | 24951880 | 1312 | COMT | umls:C0016053 | BeFree | Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a meta-analysis. | 0.023451079 | 2014 | COMT;MIR4761 | 22 | 19963748 | G | A |
| rs4818 | 21120493 | 1312 | COMT | umls:C0016053 | BeFree | These results suggest that SNPs rs4680 and rs4818 of the COMT gene may be associated with fibromyalgia and pain sensitivity in FS Brazilian patients. | 0.023451079 | 2012 | COMT;MIR4761 | 22 | 19963684 | C | G,T |
| rs6311 | 18196244 | 3356 | HTR2A | umls:C0016053 | BeFree | The objective of this study was to determine the potential effects of single nucleotide polymorphisms (SNPs) in catechol-O-methyltransferase (COMT) (rs4680) and 5-hydroxytryptamine (serotonin) 2A (5-HT2A) receptor (rs6313 and rs6311) genes on susceptibility to FMS. | 0.003995683 | 2008 | HTR2A | 13 | 46897343 | C | T |
| rs6313 | 18196244 | 3356 | HTR2A | umls:C0016053 | BeFree | The objective of this study was to determine the potential effects of single nucleotide polymorphisms (SNPs) in catechol-O-methyltransferase (COMT) (rs4680) and 5-hydroxytryptamine (serotonin) 2A (5-HT2A) receptor (rs6313 and rs6311) genes on susceptibility to FMS. | 0.003995683 | 2008 | HTR2A | 13 | 46895805 | G | A |
| rs6313 | 22124593 | 3356 | HTR2A | umls:C0016053 | BeFree | Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility. | 0.003995683 | 2011 | HTR2A | 13 | 46895805 | G | A |
| rs6313 | 11732859 | 3356 | HTR2A | umls:C0016053 | BeFree | Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. | 0.003995683 | 2001 | HTR2A | 13 | 46895805 | G | A |
| rs6313 | 21120487 | 3356 | HTR2A | umls:C0016053 | BeFree | This meta-analysis demonstrates that the 5-HT2A receptor 102T/C polymorphism confers susceptibility to fibromyalgia. | 0.003995683 | 2012 | HTR2A | 13 | 46895805 | G | A |
| rs6313 | 10527809 | 3356 | HTR2A | umls:C0016053 | BeFree | The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. | 0.003995683 | 1999 | HTR2A | 13 | 46895805 | G | A |
GWASdb Annotation(Total Genotypes:13) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chr | Pos | SNP_Id | RefGene | EnsemblGene | ENCODE_Factor | ENCODE_TFBS | Chromosome_interaction | GTEx_eQTL | SNP_TFBS_affinity_GWAS3D | SNP_miRNA_target_affinity_PolymiRTS | SNP_splicing_effect_Skippy | SNP_splicing_effect_MutPred_Splice | SNP_ns_protein_effect_dbNSFP | SNP_syn_effect_Silva | SNP_phosphorylation_effect_PhosSNP | PhastCons_score | PhyloP_score | GERP++_RS | Segway_state | Ancestral_allele | ESP_AF | ESP_AFR | ESP_AFR | ESP_EUR | TG_ASN | TG_AMR | TG_AFR | TG_EUR | Type | Consequence | bStatistic | EncH3K27Ac | EncH3K4Me1 | EncH3K4Me3 | EncNucleo | OMIM | Clinvar |
| 5 | 149440045 | rs12516676 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000515068,ENSG00000182578 | ENST00000513609,ENSG00000182578 | ENST00000515239,ENSG00000182578 | NA | NA | NA | NA | Asg1-DBD-primary,7.9738 | Asg1-DBD-primary,1.3568 | Asg1-DBD-primary,24.186 | Asg1-DBD-primary,66.5157 | Asg1-DBD-primary,4.0317 | NA | NA | NA | NA | NA | NA | 0.000 | -0.741 | -3.87 | R3 | C | NA | NA | NA | NA | NA | NA | NA | NA |
| 5 | 149443298 | rs216140 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000513609,ENSG00000182578 | ENST00000515239,ENSG00000182578 | NA | NA | NA | NA | Gat1-primary,8.3728 | Gzf3-primary,10.1043 | Rdr1-DBD-primary,1.6969 | Tbf1-DBD-primary,7.3762 | Tec1-primary,5.0564 | NA | NA | NA | NA | NA | NA | 0.000 | -1.885 | -8.27 | R3 | T | NA | NA | NA | NA | NA | NA | NA | NA | Transcript |
| 5 | 149445595 | rs216145 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000513609,ENSG00000182578 | ENST00000515239,ENSG00000182578 | TFP.MAX | NA | NA | NA | Aro80-primary,1.7456 | Ecm22-primary,2.4161 | Gal4-primary,1.6751 | Gal4-primary,1.3214 | Gsm1-FL-primary,1.5537 | NA | NA | NA | NA | NA | NA | 0.000 | -0.207 | -1.11 | R5 | G | NA | NA | NA | NA | NA | NA | NA | NA | RegulatoryFeature |
| 5 | 149445921 | rs216146 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000513609,ENSG00000182578 | ENST00000515239,ENSG00000182578 | TFP.MAX | MCV-3 | NA | NA | NA | Gat1-primary,1.6676 | Gzf3-primary,1.6616 | Pbf1-primary,3.7868 | Skn7-primary,1.4239 | Skn7-primary,1.609 | NA | NA | NA | NA | NA | NA | 0.003 | 0.737 | 2.25 | R1 | T | NA | NA | NA | NA | NA | NA | NA | NA |
| 5 | 149446487 | rs216148 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000513609,ENSG00000182578 | ENST00000515239,ENSG00000182578 | TFP.MAX | TFP.MYC | NA | NA | NA | LM152,2.1818 | LM152,2.2438 | LM197,2.7663 | Pax5,1.4035 | PPARG-RXRA,3.2188 | NA | NA | NA | NA | NA | NA | 0.001 | 0.368 | 1.16 | TF0 | A | NA | NA | NA | 0.290 | 0.440 | 0.250 | 0.470 | 0.090 |
| 5 | 149447628 | rs216150 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000513609,ENSG00000182578 | ENST00000515239,ENSG00000182578 | MCV-2 | NA | NA | NA | LM7,9.6604 | LM14,5.7656 | LM23,9.2765 | LM46,1.7805 | LM46,1.7393 | NA | NA | NA | NA | NA | NA | 0.000 | -0.398 | -1.47 | R3 | G | NA | NA | NA | NA | NA | NA | NA | NA | Transcript |
| 5 | 149450132 | rs10079250 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | TFP.CTCF | TFP.RAD21 | NA | NA | NA | Cgd2_3490,3.652 | Cgd2_3490,10.0422 | Cha4-primary,59.2578 | Leu3-primary,2.8451 | Pdr1-DBD-primary,3.4557 | NA | NA | NA | CSF1R,T,G,H,P,0.589,0.97,0.983215,0.264712 | CSF1R,T,C,H,R,0.442,0.95,0.983215,0.090019 | CSF1R,T,A,H,L,0.006,0.96,0.983215,0.316504 | NA | NM_005211,TypeII+,CAC->CGC,H->R,3.25 | NM_005211,TypeII+,CAC->CGC,H->R,2.75 | NM_005211,TypeII+,CAC->CGC,H->R,4.226 | NM_005211,TypeII+,CAC->CGC,H->R,3.316 | NM_005211,TypeII-,CAC->CGC,H->R,2.364 | NM_005211,TypeIII+,CAC->CGC,H->R,3.76 | NM_005211,TypeIII+,CAC->CGC,H->R,3.967 | NM_005211,TypeIII+,CAC->CGC,H->R,5.411 | NM_005211,TypeIII+,CAC->CGC,H->R,2.273 | NM_005211,TypeIII+,CAC->CGC,H->R,4.462 | NM_005211,TypeIII+,CAC->CGC,H->R,6 | NM_005211,TypeIII+,CAC->CGC,H->R,2.593 | NM_005211,TypeIII+,CAC->CGC,H->R,3.526 | NM_005211,TypeIII-,CAC->CGC,H->R,2.923 |
| 5 | 149454918 | rs12651699 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | NA | NA | NA | NA | LM35,5.1226 | LM52,2.3039 | LM77,5.0038 | LM85,3.3137 | LM145,10.0665 | NA | NA | NA | NA | NA | NA | 0.006 | 0.000 | 0 | R1 | C | NA | NA | NA | NA | NA | NA | NA | NA | Transcript | INTRONIC | 667 |
| 5 | 149459574 | rs13188584 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000504875,ENSG00000182578 | ENST00000394307,ENSG00000182578 | ENST00000502660,ENSG00000182578 | ENST00000511344,ENSG00000182578 | MCV-3 | NA | NA | NA | Asg1-DBD-primary,23.1567 | Gal4-primary,1.5472 | Hal9-primary,6.5637 | Hal9-primary,6.5637 | Mbp1-primary,1.5609 | NA | NA | NA | NA | NA | NA | 0.000 | -0.742 | -5.46 | R5 | C | NA | NA | NA | NA | NA | NA | NA | NA | Transcript |
| 5 | 149481535 | rs1465692 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000511344,ENSG00000182578 | NA | NA | chr5,149480001,149490000,chr5,149460001,149470000,27,Hi-C | chr5,149480001,149490000,chr5,177340001,177350000,38,Hi-C | chr5,149480001,149490000,chr7,102150001,102160000,194,Hi-C | chr5,149480001,149490000,chr5,154190001,154200000,5,Hi-C | NA | Fhl1-DBD-primary,2.456 | LM33,2.4677 | LM44,1.8498 | LM46,1.3889 | LM59,1.5167 | NA | NA | NA | NA | NA | NA | 0.004 | 1.214 | 1.97 | R2 | T | NA | NA | NA | NA | NA | NA | NA | NA | Intergenic |
| 5 | 149485772 | rs6865659 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000511344,ENSG00000182578 | MCV-3 | NA | chr5,149480001,149490000,chr5,149460001,149470000,27,Hi-C | chr5,149480001,149490000,chr5,177340001,177350000,38,Hi-C | chr5,149480001,149490000,chr7,102150001,102160000,194,Hi-C | chr5,149480001,149490000,chr5,154190001,154200000,5,Hi-C | NA | LM58,5.9133 | LM165,4.6582 | LM174,7.3932 | dl_1,2.3765 | Gfi,1.3755 | NA | NA | NA | NA | NA | NA | 0.004 | 0.713 | 2.4 | R5 | A | NA | NA | NA | NA | NA | NA | NA | NA | Transcript |
| 5 | 149489110 | rs1010101 | NM_005211,CSF1R | ENST00000286301,ENSG00000182578 | ENST00000511344,ENSG00000182578 | MCV-6 | NA | chr5,149480001,149490000,chr5,149460001,149470000,27,Hi-C | chr5,149480001,149490000,chr5,177340001,177350000,38,Hi-C | chr5,149480001,149490000,chr7,102150001,102160000,194,Hi-C | chr5,149480001,149490000,chr5,154190001,154200000,5,Hi-C | NA | LM12,1.8026 | LM31,1.6547 | LM44,1.3206 | LM54,1938.45 | LM117,2.1234 | NA | NA | NA | NA | NA | NA | 0.001 | 0.013 | 0.133 | R4 | C | NA | NA | NA | NA | NA | NA | NA | NA | Intergenic |
| 5 | 149492455 | rs11740298 | NM_005211,CSF1R | NM_002609,PDGFRB | ENST00000286301,ENSG00000182578 | ENST00000511344,ENSG00000182578 | ENST00000261799,ENSG00000113721 | ENST00000520851,ENSG00000113721 | TFP.TFAP2A | TFP.TFAP2C | TFP.SMARCC1 | TFP.STAT3 | NA | NA | NA | Aft1-primary,2.824 | Ceh-22,1.3236 | Cgd2_3490,1.341 | Cha4-primary,3.4829 | Rap1-FL-primary,1.6087 | NA | NA | NA | NA | NA | NA | 0.000 | -0.119 | -0.622 | TF1 | C | NA | NA | NA | NA | NA | NA |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0016053 | celecoxib | D000068579 | - | fibromyalgia | MESH:D005356 | therapeutic | 15106034 | ||
| C0016053 | lidocaine | D008012 | 137-58-6 | fibromyalgia | MESH:D005356 | therapeutic | 12509636 | ||
| C0016053 | pregabalin | D000069583 | - | fibromyalgia | MESH:D005356 | therapeutic | 18765137 | ||
| C0016053 | tramadol | D014147 | 27203-92-5 | fibromyalgia | MESH:D005356 | therapeutic | 10985875 | ||
| C0016053 | vitamin a | D014801 | 11103-57-4 | fibromyalgia | MESH:D005356 | marker/mechanism | 7610649 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |